Evocalcet is a Small Molecule owned by Mitsubishi Tanabe Pharma, and is involved in 11 clinical trials, which were completed.

MT-4580 is an agonist of extracellular G-protein-coupled calcium sensing receptor (CASR) which is an essential component of calcium homeostasis. CASR forms stable homodimeric cell-membrane complexes, which signal upon binding of extracellular calcium-ions (Ca[++]). In the parathyroid glands, this results in down regulation of gene expression of the main short-term regulator of calcium homeostasis, parathyroid hormone (PTH), as well as diminished secretion of already synthesized PTH. At the same time, renal calcium excretion is unregulated and sodium-chloride excretion is down regulated. Ca(++) binding to CASR is highly cooperative within the physiological Ca(++) concentration range, leading to a steep dose-response curve, which results in tight control of serum calcium levels.

The revenue for Evocalcet is expected to reach a total of $1.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Evocalcet NPV Report.

Evocalcet is originated and owned by Mitsubishi Tanabe Pharma. Kyowa Kirin is the other company associated in development or marketing of Evocalcet.

Evocalcet Overview

Evocalcet (Orkedia/ KHK7580) is a new type of oral calcimimetics agent. It is formulated as film coated tablets for oral route of administration. Orkedia is indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis.It is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy

Evocalcet is under development for the treatment of secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism in hemodialysis patients

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Evocalcet

Report Segments
  • Innovator (NME)
Drug Name
  • Evocalcet
Administration Pathway
  • Oral
Therapeutic Areas
  • Hormonal Disorders
  • Nutritional Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.